Here’s Why Regeneron Pharmaceuticals (REGN) Fell in Q2

Core Insights - Chautauqua Capital Management's second quarter 2025 investor letter indicates a significant shift in global equity markets, moving from notable losses to new highs, influenced by tariff announcements and subsequent market recovery [1] - The Baird Chautauqua International Growth Fund underperformed its benchmark during the quarter despite the overall market recovery [1] Company Performance - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported a one-month return of -2.89% and a 52-week loss of 46.36%, with a closing stock price of $563.90 and a market capitalization of $59.766 billion as of September 26, 2025 [2] - In the second quarter of 2025, Regeneron's total revenues reached $3.7 billion, reflecting a 4% growth year-over-year [4] Drug Pipeline Insights - Regeneron reported mixed results for its pipeline drug itepekimab in Chronic Obstructive Pulmonary Disease (COPD), with one of two trials meeting expectations; however, it is not expected to be a core driver for the company's shares [3]